US 8075903
Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4
granted A61KA61K2039/5254A61K2039/5256
Quick answer
US patent 8075903 (Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3′-UTR of dengue types 1, 2, 3, and 4 or antigenic chimeric dengue viruses 1, 2, 3, and 4) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Dec 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Department of Health and Human Services
- Grant date
- Tue Dec 13 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 08 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 36
- CPC classes
- A61K, A61K2039/5254, A61K2039/5256, A61K2039/70, A61K39/12